Charles Lapp: Difference between revisions

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
m (Text replacement - "Talks & interviews" to "Talks and interviews")
m (Text replacement - "author-link8 = | last8" to "author-link7 = | last8")
 
(229 intermediate revisions by 2 users not shown)
Line 1: Line 1:
[[File:Dr. Charles Lapp.png|right|Source: Hunter-Hopkins Center]]
[[File:Dr. Charles Lapp.png|right|Source: Hunter-Hopkins Center]]
'''Charles W. Lapp''', MD, is a retired Internal Medicine physician and the Medical Director Emeritus at [[Hunter-Hopkins Center]] in Charlotte, North Carolina, [[United States|US]], which has a practice specializing in [[ME/CFS]], [[FM]], and related conditions. Earlier in his career, he practiced family medicine and pediatrics in Raleigh, NC.<ref name=":1">{{Cite web|url=https://drlapp.com/news/me-letter-february-2018/#retires|title=ME Letter February 2018|language=en-US|access-date=2018-12-23|date=|website=|last=|first=|authorlink=|last2=|first2=|authorlink2=|archive-url=|archive-date=|dead-url=}}</ref> He became interested in [[ME/CFS]] following an outbreak of three small epidemics of a chronic fatiguing illness in the Raleigh area. [[1984 Chapel Hill outbreak|One of these outbreaks]] was among all the members of the N.C. Symphony Orchestra.<ref>{{Cite web|url=http://newsok.com/article/3366622|title=Cause of illness remains unknown|last=Garloch|first=Karen|date=2009|website=NewsOK|archive-url=|archive-date=|dead-url=|access-date=|authorlink=|last2=|first2=|authorlink2=}}</ref>
'''Charles W. Lapp''', MD, is a retired Internal Medicine physician and the Medical Director Emeritus at [[Hunter-Hopkins Center]] in Charlotte, North Carolina, [[United States|US]], which has a practice specializing in [[ME/CFS]], [[FM|fibromyalgia]], and related conditions.<ref>{{Cite web | url = https://drlapp.com/staff/curriculum-vitae-charles-w-lapp-md/ | title = Curriculum Vitae – Charles W. Lapp, MD | last = | first = | authorlink = | date = | website = Hunter-Hopkins Center|language=en-US| archive-url = | archive-date = |url-status = | access-date=2020-10-26}}</ref> Earlier in his career, he practiced family medicine and pediatrics in Raleigh, NC.<ref name="retirement"/> He became interested in [[ME/CFS]] following an outbreak of three small epidemics of a chronic fatiguing illness in the Raleigh area. [[1984 Chapel Hill outbreak|One of these outbreaks]] was among all the members of the N.C. Symphony Orchestra.<ref>{{Cite web | url = http://newsok.com/article/3366622 | title = Cause of illness remains unknown | last = Garloch | first = Karen | date = 2009 | website = NewsOK| archive-url = | archive-date = |url-status = | access-date= | authorlink = }}</ref>


From 1992 to 1995 Dr. Lapp acted as Medical Director of the Cheney Clinic in Charlotte, in collaboration with Dr. [[Paul Cheney]]. In August 1995, Dr. Lapp opened the Hunter-Hopkins Center in Charlotte, North Carolina where he practiced until his retirement in 2018.<ref name=":1" /> His center does testing for disability insurance such as the 2-day [[Cardiopulmonary exercise testing]] ([[CPET]]) and a computer-assisted cognitive function test.
From 1992 to 1995 Dr. Lapp acted as Medical Director of the Cheney Clinic in Charlotte, in collaboration with Dr. [[Paul Cheney]]. In August 1995, Dr. Lapp opened the [[Hunter-Hopkins Center]] in Charlotte, North Carolina where he practiced until his retirement in 2018.<ref name="retirement" /> His center does testing for disability insurance such as the [[two-day cardiopulmonary exercise test]] (2-day CPET) and a computer-assisted cognitive function test.


Following Dr. Lapp's retirement in 2018, the Hunter-Hopkins Center director became Dr. [[Vincent Hillman|Vincent F. Hillman]] with Dr. [[Laura Black]] continuing on staff.<ref name=":1" />
Following Dr. Lapp's retirement in 2018, the Hunter-Hopkins Center director became Dr. [[Vincent Hillman|Vincent F. Hillman]] with Dr. [[Laura Black]] continuing on staff.<ref name="retirement">{{Cite web | url = https://drlapp.com/news/me-letter-february-2018/#retires | title = Dr. Lapp Retires and Dr. Vincent Hillman Takes the Helm | date = 2018-02-12|language=en-US|access-date=2018-12-23 | website = Hunter-Hopkins Center | last = Lapp | first = Charles | authorlink = Charles Lapp|archive-url=|archive-date=|url-status=}}</ref>
 
Dr. Lapp serves on the editorial board of the journal, [[Fatigue: Biomedicine, Health & Behavior]], published on behalf of the [[IACFS/ME]].<ref>{{Cite web | url = https://www.tandfonline.com/action/journalInformation?show=editorialBoard&journalCode=rftg20& | title = Fatigue: Biomedicine, Health & Behavior | website = tandfonline.com|access-date=2019-11-01}}</ref>


==Awards==
==Awards==


*2009, Nelson Gantz Outstanding Clinician Award awarded to a physician who emulates Nelson Gantz's clinical acumen, his passion for medicine, and his empathy for persons with CFS/FM awarded by [[International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis|IACFS/ME.]]<ref>{{Cite web|url=http://iacfsme.org/Organization/Former-IACFS-ME-Awardees.aspx|title=Former IACFS/ME Awardees|last=International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis|first=|authorlink=International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis|last2=|first2=|authorlink2=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref>
*2009, Nelson Gantz Outstanding Clinician Award awarded to a physician who emulates Nelson Gantz's clinical acumen, his passion for medicine, and his empathy for persons with CFS/FM awarded by [[International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis]].<ref>{{Cite web | url = https://www.iacfsme.org/iacfs-me-awardees | title = IACFS/ME Awardees | website =  
IACFS/ME|access-date=2020-04-23}}</ref>


==IOM Committee on Diagnostic Criteria for ME/CFS==
==IOM Committee on Diagnostic Criteria for ME/CFS==
Dr Lapp was a reviewer for the [[Institute of Medicine report|2015 report]] produced by the [[Institute of Medicine]]'s Committee on Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.<ref>{{Cite web|url=https://www.nap.edu/resource/19012/MECFS_Powerpoint.pdf|title=ME/CFS Presentation|last=Institute of Medicine|first=|authorlink=Institute of Medicine|last2=|first2=|authorlink2=|date=|website=www.nap.edu|archive-url=|archive-date=|dead-url=|access-date=2018-12-23}}</ref>
Dr Lapp was a reviewer for the [[Institute of Medicine report|2015 report]] produced by the [[Institute of Medicine]]'s Committee on Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.<ref>{{Cite web | url = https://www.nap.edu/resource/19012/MECFS_Powerpoint.pdf | title=ME/CFS Presentation | last = Institute of Medicine | first = | authorlink = Institute of Medicine | date = | website = National Academies Press| archive-url = | archive-date = |url-status = | access-date=2018-12-23}}</ref>


==Pediatric Case Definition==
==Pediatric Case Definition==
Line 18: Line 21:


==Clinical Trials==
==Clinical Trials==
The [[Hunter-Hopkins Center]] was one of two clinical sites participating in the [[Hemispherx Biopharma]] 511/open label [[Ampligen]] trials to gain [[FDA]] approval, which was ultimately unsuccessful. The [[Ampligen]] phase III trial results were published in 2012.<ref name="Strayer, 2012" /><ref name=":0">{{Cite web|url=https://drlapp.com/research/#tabs_6431815605c1f658582e55-tab_2|title=Ampligen {{!}} Research {{!}} Hunter-Hopkins Center, P.A.|last=Hunter-Hopkins Center|first=|authorlink=Hunter-Hopkins Center|last2=|first2=|authorlink2=|date=|website=|language=en-US|archive-url=|archive-date=|dead-url=|access-date=2018-12-23}}</ref> Ampligen, a brand name for '''Rintatolimod''', is an IV medication, and was given twice weekly at the Hunter-Hopkins infusion room during the trial. The Hunter-Hopkins Center is currently one of four clinics that can administer Ampligen in the US.<ref name=":0" />
The [[Hunter-Hopkins Center]] was one of two clinical sites participating in the [[Hemispherx Biopharma]] 511/open label [[Ampligen]] trials to gain [[FDA]] approval, which was ultimately unsuccessful. The [[Ampligen]] phase III trial results were published in 2012.<ref name="Strayer, 2012" /><ref name=":0">{{Cite web | url = https://drlapp.com/research/#tabs_6431815605c1f658582e55-tab_2 | title = Ampligen {{!}} Research {{!}} Hunter-Hopkins Center, P.A. | last = Hunter-Hopkins Center | first = | authorlink = Hunter-Hopkins Center | date = | website = |language=en-US| archive-url = | archive-date = |url-status = | access-date=2018-12-23}}</ref> Ampligen, a brand name for '''Rintatolimod''', is an IV medication, and was given twice weekly at the Hunter-Hopkins infusion room during the trial. The Hunter-Hopkins Center is currently one of four clinics that can administer Ampligen in the US.<ref name=":0" />


==Clinic location==
==Clinic location==
Dr Lapp retired in 2018, other physicians with expertise in ME/CFS can be contacted at the clinic he founded.


:Hunter-Hopkins Center
:Hunter-Hopkins Center
Line 28: Line 33:
:Email: drlapp@drlapp.net
:Email: drlapp@drlapp.net


==Notable Studies==
==Notable studies==


*1997, Management of Chronic Fatigue Syndrome in Children: A Practicing Clinician's Approach<ref>Charles W. Lapp. (1997). Management of Chronic Fatigue Syndrome in Children: A Practicing Clinician's Approach. ''Journal of Chronic Fatigue Syndrome,'' Vol. 3, Iss. 2, pp 59-76. http://dx.doi.org/10.1300/J092v03n02_07</ref>
*1997, Management of Chronic Fatigue Syndrome in Children: A Practicing Clinician's Approach<ref>Charles W. Lapp. (1997). Management of Chronic Fatigue Syndrome in Children: A Practicing Clinician's Approach. ''Journal of Chronic Fatigue Syndrome,'' Vol. 3, Iss. 2, pp 59-76. http://dx.doi.org/10.1300/J092v03n02_07</ref>
Line 37: Line 42:
*2009, Severe versus Moderate criteria for the new [[pediatric]] case definition for [[ME/CFS]]<ref name="Jason, Dec2009" /> [https://www.ncbi.nlm.nih.gov/pubmed/19513826 (Abstract)]
*2009, Severe versus Moderate criteria for the new [[pediatric]] case definition for [[ME/CFS]]<ref name="Jason, Dec2009" /> [https://www.ncbi.nlm.nih.gov/pubmed/19513826 (Abstract)]
*2012, A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist [[rintatolimod]] in severe cases of chronic fatigue syndrome<ref name="Strayer, 2012" /> [http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0031334 (Full Text)]
*2012, A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist [[rintatolimod]] in severe cases of chronic fatigue syndrome<ref name="Strayer, 2012" /> [http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0031334 (Full Text)]
*2014, No association found between the detection of either [[xenotropic murine leukemia virus-related virus]] or polytropic murine leukemia virus and [[chronic fatigue syndrome]] in a blinded, multi-site, prospective study by the establishment and use of the [[SolveCFS BioBank & Patient Registry|SolveCFS BioBank]]<ref>{{Cite journal|last=Irlbeck|first=David M.|last2=Vernon|first2=Suzanne D.|author-link2=Suzanne Vernon|last3=McCleary|first3=K. Kimberly|author-link3=Kim McCleary|last4=Bateman|first4=Lucinda|author-link4=Lucinda Bateman|last5=Klimas|first5=Nancy G.|author-link5=Nancy Klimas|last6=Lapp|first6=Charles W.|author-link6=Charles Lapp|last7=Peterson|first7=Daniel L.|author-link7=Daniel Peterson|last8=Brown|first8=James R.|last9=Remlinger|first9=Katja S.|date=2014|title=No association found between the detection of either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus and chronic fatigue syndrome in a blinded, multi-site, prospective study by the establishment and use of the SolveCFS BioBank|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236736/|journal=BMC Research Notes|volume=7|pages=461|doi=10.1186/1756-0500-7-461|via=|last10=Wilfret|last11=Gerondelis|first11=Peter|first10=David A.}}</ref> [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236736/ (Full Text)]
*2014, No association found between the detection of either [[xenotropic murine leukemia virus-related virus]] or polytropic murine leukemia virus and [[chronic fatigue syndrome]] in a blinded, multi-site, prospective study by the establishment and use of the [[SolveCFS BioBank & Patient Registry|SolveCFS BioBank]]<ref>{{Cite journal | last = Irlbeck | first = David M. | last2 = Vernon | first2 = Suzanne D. | author-link2 = Suzanne Vernon | last3 = McCleary | first3 = K. Kimberly | author-link3 = Kim McCleary | last4 = Bateman | first4 = Lucinda | author-link4 = Lucinda Bateman | last5 = Klimas | first5 = Nancy G. | author-link5 = Nancy Klimas | last6 = Lapp | first6 = Charles W. | author-link6 = Charles Lapp | last7 = Peterson | first7 = Daniel L. | author-link7 = Daniel Peterson | last8 = Brown | first8 = James R. | last9 = Remlinger | first9 = Katja S.| date = 2014 | title = No association found between the detection of either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus and chronic fatigue syndrome in a blinded, multi-site, prospective study by the establishment and use of the SolveCFS BioBank | url =https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236736/ | journal = BMC Research Notes | volume = 7 | pages = 461|doi=10.1186/1756-0500-7-461|via= | last10 = Wilfret | last11 = Gerondelis | first11 = Peter | first10 = David A.}}</ref> [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236736/ (Full Text)]
*2016, [[CDC]] Grand Rounds: [[Chronic Fatigue Syndrome]] — Advancing Research and Clinical Education. Morbidity and [[Mortality]] Weekly Report<ref>{{Cite journal|last1=Unger|first1=ER|authorlink1=Elizabeth Unger|last2=Lin|first2=JS|authorlink2=Jin-Mann Sally Lin|last3=Brimmer|first3=DJ|authorlink3=|last4=Lapp|first4=CW|authorlink4=Charles Lapp|last5=Komaroff|first5=AL|authorlink5=Anthony Komaroff|last6=Nath|first6=A|authorlink6=Avindra Nath|last7=Laird|first7=S|authorlink7=| last8=Iskander|first8=J|authorlink8=John Iskander|title=CDC Grand Rounds: Chronic Fatigue Syndrome — Advancing Research and Clinical Education|journal=Morbidity and Mortality Weekly Report|volume=65|issue=5051|page=1434–1438|date=2016|doi=10.15585/mmwr.mm655051a4}} - </ref> - [https://www.cdc.gov/mmwr/volumes/65/wr/mm655051a4.htm (Full Text)]
*2016, [[CDC]] Grand Rounds: [[Chronic Fatigue Syndrome]] — Advancing Research and Clinical Education. Morbidity and [[Mortality]] Weekly Report<ref>{{Cite journal | last1 = Unger | first1 = ER | authorlink = Elizabeth Unger | last2 = Lin | first2 = JS | author-link2 = Jin-Mann Sally Lin | last3 = Brimmer | first3 = DJ | author-link3 = | last4 = Lapp | first4 = CW | author-link4 = Charles Lapp | last5 = Komaroff | first5 = AL | author-link5 = Anthony Komaroff | last6 = Nath | first6 = A | author-link6 = Avindra Nath | last7 = Laird | first7 = S | author-link7 = | last8 = Iskander | first8 = J | author-link8 = John Iskander | title = CDC Grand Rounds: Chronic Fatigue Syndrome — Advancing Research and Clinical Education | journal = Morbidity and Mortality Weekly Report | volume = 65 | issue = 5051| page=1434–1438 | date = 2016 | doi=10.15585/mmwr.mm655051a4}} - </ref> - [https://www.cdc.gov/mmwr/volumes/65/wr/mm655051a4.htm (Full Text)]
*2017, Multi-Site Clinical Assessment of [[ME/CFS|Myalgic Encephalomyelitis/Chronic Fatigue Syndrome]] (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study<ref name="Unger, 2017" /> [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565838/ (Full Text)]
*2017, Multi-Site Clinical Assessment of [[ME/CFS|Myalgic Encephalomyelitis/Chronic Fatigue Syndrome]] (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study<ref name="Unger, 2017" /> [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565838/ (Full Text)]
*2019, Initiating care of a patient with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)<ref>{{Cite journal|last=Lapp|first=Charles W.|author-link=Charles Lapp|author-link2=|author-link3=|author-link4=|author-link5=|date=Jan 2019|title=Initiating Care Of A Patient With Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS)|url=https://www.frontiersin.org/articles/10.3389/fped.2018.00415/abstract|journal=Frontiers in Pediatrics|volume=|issue=|pages=|doi=10.3389/fped.2018.00415|quote=|via=}}</ref> [https://www.frontiersin.org/articles/10.3389/fped.2018.00415/full (Full text)]
*2019, Initiating care of a patient with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)<ref>{{Cite journal | last = Lapp | first = Charles W. | authorlink = Charles Lapp | date = Jan 2019 | title = Initiating Care Of A Patient With Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS) | url = https://www.frontiersin.org/articles/10.3389/fped.2018.00415/abstract | journal = Frontiers in Pediatrics | volume = | issue = | pages = |doi=10.3389/fped.2018.00415|quote=|via=}}</ref> [https://www.frontiersin.org/articles/10.3389/fped.2018.00415/full (Full text)]
*2019, Estimating Prevalence, Demographics, and Costs of ME/CFS Using Large Scale Medical Claims Data and Machine Learning<ref>{{Cite journal|last=Proskauer|first=Charmian|author-link=Charmian Proskauer|last2=Rowe|first2=Peter C.|author-link2=Peter Rowe|last3=Lapp|first3=Charles W.|author-link3=Charles Lapp|last4=DeMaria|first4=Alfred Jr|author-link4=|last5=Bateman|first5=Lucinda|author-link5=Lucinda Bateman|last6=Attewell|first6=John R.|last7=Proskauer|first7=Daniel|last8=Kiernicki|first8=David J.|last9=Adebayo|first9=Seyi|date=2019|title=Estimating Prevalence, Demographics, and Costs of ME/CFS Using Large Scale Medical Claims Data and Machine Learning|url=https://www.frontiersin.org/articles/10.3389/fped.2018.00412/full|journal=Frontiers in Pediatrics|language=English|volume=6|issue=|pages=|doi=10.3389/fped.2018.00412|issn=2296-2360|pmc=|pmid=30671425|quote=|via=}}</ref> [https://www.frontiersin.org/articles/10.3389/fped.2018.00412/full (Full text)]
*2019, Estimating Prevalence, Demographics, and Costs of ME/CFS Using Large Scale Medical Claims Data and Machine Learning<ref>{{Cite journal | last = Proskauer | first = Charmian | authorlink = Charmian Proskauer | last2 = Rowe | first2 = Peter C. | author-link2 = Peter Rowe | last3 = Lapp | first3 = Charles W. | author-link3 = Charles Lapp | last4 = DeMaria | first4 = Alfred Jr | author-link4 = | last5 = Bateman | first5 = Lucinda | author-link5 = Lucinda Bateman | last6 = Attewell | first6 = John R. | last7 = Proskauer | first7 = Daniel | last8 = Kiernicki | first8 = David J. | last9 = Adebayo | first9 = Seyi | date = 2019 | title=Estimating Prevalence, Demographics, and Costs of ME/CFS Using Large Scale Medical Claims Data and Machine Learning | url =https://www.frontiersin.org/articles/10.3389/fped.2018.00412/full | journal = Frontiers in Pediatrics|language=English | volume = 6 | issue = | pages = |doi=10.3389/fped.2018.00412|issn=2296-2360|pmc=|pmid=30671425|quote=|via=}}</ref> [https://www.frontiersin.org/articles/10.3389/fped.2018.00412/full (Full text)]


==Talks and interviews==
==Talks and interviews==


*[http://www.cfidsselfhelp.org/library/dr-lapp's-recommedations-supplements Dr. Lapp’s recommendations on supplements]<ref>{{Cite web|url=http://www.cfidsselfhelp.org/library/dr-lapp%27s-recommedations-supplements|title=Dr Lapp's Recommendations on Supplements {{!}} ME/CFS & Fibromyalgia Self-Help|last=Campbell|first=Bruce|authorlink=Bruce Campbell|last2=|first2=|authorlink2=|date=|website=www.cfidsselfhelp.org|archive-url=|archive-date=|dead-url=|access-date=2018-12-23}}</ref>
*[http://www.cfidsselfhelp.org/library/dr-lapp's-recommedations-supplements Dr. Lapp’s recommendations on supplements]<ref>{{Cite web | url = http://www.cfidsselfhelp.org/library/dr-lapp%27s-recommedations-supplements | title = Dr Lapp's Recommendations on Supplements {{!}} ME/CFS & Fibromyalgia Self-Help | last = Campbell | first = Bruce | authorlink = Bruce Campbell | date = | website = cfidsselfhelp.org| archive-url = | archive-date = |url-status = | access-date=2018-12-23}}</ref>
*16 Feb 2016, CDC Grand Rounds - Chronic Fatigue Syndrome: Advancing Research and Clinical Education with Charles Lapp, MD, [[Elizabeth Unger]], PhD, MD, [[Anthony Komaroff]], MD and [[Avindra Nath]], MD
*16 Feb 2016, CDC Grand Rounds - Chronic Fatigue Syndrome: Advancing Research and Clinical Education with Charles Lapp, MD, [[Elizabeth Unger]], PhD, MD, [[Anthony Komaroff]], MD and [[Avindra Nath]], MD


Line 58: Line 63:


==Open Letter to ''The Lancet''==  
==Open Letter to ''The Lancet''==  
Three open letters to the editor of ''The Lancet'' urged the editor to commission a fully independent review of the [[PACE trial]], which the journal had published in 2011. In 2016, Dr. Lapp, along with 42 colleagues in the [[ME/CFS]] field, signed the second letter.<ref>{{Cite web|url=http://www.virology.ws/2016/02/10/open-letter-lancet-again/|title=Open Letter Lancet Again|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref> In 2018, Dr. Lapp, with more than 100 colleagues in the [[ME/CFS]] field, signed the third letter.<ref>{{Cite web|url=http://www.virology.ws/2018/06/19/trial-by-error-an-open-letter-to-the-lancet-two-years-on/|title=An Open Letter to The Lancet, Two Years On|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref>
Three open letters to the editor of ''The Lancet'' urged the editor to commission a fully independent review of the [[PACE trial]], which the journal had published in 2011. In 2016, Dr. Lapp, along with 42 colleagues in the [[ME/CFS]] field, signed the second letter.<ref>{{Cite web | url = http://www.virology.ws/2016/02/10/open-letter-lancet-again/ | title = Open Letter Lancet Again | last = | first = | date = | website = | archive-url = | archive-date = |url-status = | access-date=}}</ref> In 2018, Dr. Lapp, with more than 100 colleagues in the [[ME/CFS]] field, signed the third letter.<ref>{{Cite web | url = http://www.virology.ws/2018/06/19/trial-by-error-an-open-letter-to-the-lancet-two-years-on/ | title = An Open Letter to The Lancet, Two Years On | last = | first = | date = | website = | archive-url = | archive-date = |url-status = | access-date=}}</ref>


*10 February 2016, [http://www.virology.ws/2016/02/10/open-letter-lancet-again/ An open letter to The Lancet, again - Virology blog]
*10 February 2016, [http://www.virology.ws/2016/02/10/open-letter-lancet-again/ An open letter to The Lancet, again - Virology blog]
Line 73: Line 78:
*2012, [http://drlapp.com/ask-the-doctor/what-are-the-most-important-things-to-remember-about-cfs-fm/ What Are The Most Important Things To Remember About CFS/FM?]
*2012, [http://drlapp.com/ask-the-doctor/what-are-the-most-important-things-to-remember-about-cfs-fm/ What Are The Most Important Things To Remember About CFS/FM?]
*[http://drlapp.com/staff/curriculum-vitae-charles-w-lapp-md/ Curriculum Vitae - Charles W. Lapp, MD]
*[http://drlapp.com/staff/curriculum-vitae-charles-w-lapp-md/ Curriculum Vitae - Charles W. Lapp, MD]
*2018, [https://www.healthrising.org/blog/2018/03/28/lapp-chronic-fatigue-syndrome-fibromyalgia-pioneer-retires/ An ME/CFS and FM Pioneer Says Good-bye: The Charles Lapp Interview]<ref>{{Cite web|url=https://www.healthrising.org/blog/2018/03/28/lapp-chronic-fatigue-syndrome-fibromyalgia-pioneer-retires/|title=An ME/CFS and FM Pioneer Says Good-bye: The Charles Lapp Interview|last=Johnson|first=Cort|authorlink=Cort Johnson|last2=|first2=|authorlink2=|date=2018-03-28|website=[[Health Rising]]|language=en-GB|archive-url=|archive-date=|dead-url=|access-date=2018-12-23}}</ref>
*2018, [https://www.healthrising.org/blog/2018/03/28/lapp-chronic-fatigue-syndrome-fibromyalgia-pioneer-retires/ An ME/CFS and FM Pioneer Says Good-bye: The Charles Lapp Interview]<ref>{{Cite web | url = https://www.healthrising.org/blog/2018/03/28/lapp-chronic-fatigue-syndrome-fibromyalgia-pioneer-retires/ | title = An ME/CFS and FM Pioneer Says Good-bye: The Charles Lapp Interview | last = Johnson | first = Cort | authorlink = Cort Johnson | date = 2018-03-28 | website = [[Health Rising]]|language=en-GB| archive-url = | archive-date = |url-status = | access-date=2018-12-23}}</ref>


==See also==
==See also==
 
*[[Hunter-Hopkins Center]]
*[[NIH Post-Infectious ME/CFS Study]]
*[[NIH Post-Infectious ME/CFS Study]]
*[[Ampligen]]
*[[Ampligen]]
*[[1984 Chapel Hill outbreak]]
*[[1984 Chapel Hill outbreak]]
*Dr. [[Laura Black]]
*Dr [[Vincent Hillman|Vincent F. Hillman]]
*Dr [[Laura Black]]


==References==
==References==
<references>
<references>
<ref name="Jason, Dec2009">{{Citation
<ref name="Jason, Dec2009">{{Citation | last = Jason | first1 = Leonard | author-link1 = Leonard Jason | last2 = Porter | first2 = Nicole | author-link2 = Nicole Porter | last3 = Shelleby | first3 = E | author-link3 = | last4 = Till | first4 = L | author-link4 = | last5 = Bell | first5 = David S | author-link5 = David Bell | last6 = Lapp | first6 = Charles W | author-link6 = Charles Lapp | last7 =Rowe | first7 = Kathy | author-link8 = Kathy Rowe | last8 = De Meirleir | first8 = Kenny | author-link8 = Kenny De Meirleir | title = Severe versus Moderate criteria for the new pediatric case definition for ME/CFS | journal = Child Psychiatry and Human Development | volume = 40 | issue = 4 | page = 609-20 | date = 2009 | pmid = | doi = 10.1007/s10578-009-0147-8 }}</ref>
| last1  = Jason             | first1 = Leonard           | authorlink1 = Leonard Jason
<ref name="JasonL2006paed">{{citation | last = Jason | first1 = Leonard A | author-link1 = Leonard Jason | last2 = Jordan | first2 = Karen | author-link2 = Karen Jordan | last3 = Miike | first3 = Teruhisa | author-link3 = Teruhisa Miike | last4 = Bell | first4 = David S | author-link4 = David Bell | last5 = Lapp | first5 = Charles| author-link5 = Charles Lapp | last6 = Torres-Harding | first6 = Susan | author-link6 = Susan Torres-Harding | last7 =Rowe | first7 = Kathy | author-link8 = Kathy Rowe | last8 = Gurwitt | first8 = Alan | author-link8 = Alan Gurwitt | last9 = De Meirleir | first9 = Kenny | author-link9 = Kenny de Meirleir | last10 = Van Hoof | first10 = Elke LS | author-link10 = Elke Van Hoof | title = A Pediatric Case Definition for Myalgic Encephalomyelitis and Chronic Fatigue Syndrome | journal = Journal of Chronic Fatigue Syndrome | volume = 13 | issue = 2-3 | pages = 1-44 | date = 2006 | doi = 10.1300/J092v13n02_01 | url = https://solvecfs.org/wp-content/uploads/2013/06/pediatriccasedefinitionshort.pdf }}</ref>
| last2   = Porter           | first2 = Nicole             | authorlink2 = Nicole Porter
<ref name="Strayer, 2012">{{Citation | last =Strayer | first1 = DR | author-link1 = David Strayer | last2 = Carter | first2 = WA | author-link2 = William Carter | last3 = Stouch | first3 = BC | author-link3 = | last4 = Stevens | first4 = SR | author-link4 = Staci Stevens | last5 = Bateman | first5 = L | author-link5 = Lucinda Bateman | last6 = Cimoch | first6 = PJ | author-link6 = | last7 =Lapp | first7 = CW | author-link8 = Charles Lapp | last8 = Peterson | first8 = DL | author-link8 = Daniel Peterson | last9 = Chronic Fatigue Syndrome AMP-516 Study Group | author-link9 = | last10 = Mitchell | first10 = WM | author-link10 = William Mitchell | title = A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome. | journal = PLoS One | volume = 7 | issue = 3 | page = e31334 | date = 2012 | pmid = 22431963 | doi = 10.1371/journal.pone.0031334 }}</ref>
| last3   = Shelleby         | first3 = E                 | authorlink3 =  
<ref name="Unger, 2017">{{Citation | last =Unger | first1 = Elizabeth R. | author-link1 = Elizabeth Unger | last2 = Lin | first2 = Jin-Mann S. | author-link2 = Jin-Mann Sally Lin | last3 = Tian | first3 = Hao | author-link3 = | last4 = Natelson | first4 = Benjamin H. | author-link4 = Benjamin Natelson | last5 = Lange | first5 = Gudrun | author-link5 = Gudrun Lange | last6 = Vu | first6 = Diana | author-link6 = | last7 =Blate | first7 = Michelle | author-link7 = | last8 = Klimas | first8 = Nancy G. | author-link8 =  Nancy Klimas | last9 = Balbin | first9 = Elizabeth G. | author-link9 = | last10 = Bateman | first10 = Lucinda | author-link10 = Lucinda Bateman | last11 = Allen | first11 = Ali | author-link11 = | last12 = Lapp | first12 = Charles W. | author-link12 =  Charles Lapp | last13 = Springs | first13 = Wendy | author-link13 = | last14 = Kogelnik | first14 = Andreas M. | author-link14 = Andreas Kogelnik | last15 = Phan | first15 = Catrina C. | author-link15 = | last16 = Danver | first16 = Joan | author-link16 = | last17 = Podell | first17 = Richard N. | author-link17 =  Richard Podell | last18 = Fitzpatrick | first18 = Trisha | author-link18 = | last19 = Peterson | first19 = Daniel L. | author-link19 = Daniel Peterson | last20 = Gottschalk | first20 = C. Gunnar| author-link20 =  Gunnar Gottschalk | last21 = Rajeevan | first21 = Mangalathu S. | author-link21 = Mangalathu Rajeevan | last22 = MCAM Study Group | title = Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study. | journal = American Journal of Epidemiology | volume = 1-10 | issue = | page = | date = 2017 | pmid = | doi = 10.1093/aje/kwx029 }}</ref>
| last4   = Till             | first4 = L                 | authorlink4 =  
<ref name="Van Hoof, 2007">{{Citation | last =Van Hoof | first1 = E | author-link1 = Elke Van Hoof | last2 = De Becker | first2 = P | author-link2 = Pascale De Becker | last3 = Lapp | first3 = C | author-link3 = Charles Lapp | last4 = Cluydts | first4 = R | author-link4 = | last5 = De Meirleir | first5 = K | author-link5 = Kenny de Meirleir | title = Defining the Occurrence and Influence of Alpha-Delta Sleep in Chronic Fatigue Syndrome | journal = The American Journal of the Medical Sciences | volume = 333 | issue = 2 | page = 78-84 | date = 2007 | pmid = 17301585 | doi = }}</ref>
| last5   = Bell             | first5 = David S           | authorlink5 = David Bell
<ref name="Vojdani, 1998">{{Citation | last =Vojdani | first1 = A | author-link1 = | last2 = Choppa | first2 = PC | author-link2 = | last3 = Lapp | first3 = CW | author-link3 = Charles Lapp | title = Downregulation of RNase L inhibitor correlates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic fatigue immune dysfunction syndrome | journal = J Clin Lab Immunol | volume = 50 | issue = 1 | page = 1-16 | date = 1998 | pmid = 10189612 | doi = }}</ref>
| last6   = Lapp             | first6 = Charles W         | authorlink6 = Charles Lapp
| last7   = Rowe             | first7 = Kathy             | authorlink7 = Kathy Rowe
| last8   = De Meirleir       | first8 = Kenny             | authorlink8 = Kenny De Meirleir
| title   = Severe versus Moderate criteria for the new pediatric case definition for ME/CFS
| journal = Child Psychiatry and Human Development   | volume = 40   | issue = 4   | page = 609-20
| date   = 2009
| pmid   =  
| doi     = 10.1007/s10578-009-0147-8
}}
</ref>
<ref name="JasonL2006paed">{{citation
| last1  = Jason           | first1 = Leonard A         | authorlink1 = Leonard Jason
| last2   = Jordan           | first2 = Karen             | authorlink2 = Karen Jordan
| last3   = Miike           | first3 = Teruhisa           | authorlink3 = Teruhisa Miike
| last4   = Bell             | first4 = David S           | authorlink4 = David Bell
| last5   = Lapp             | first5 = Charles           | authorlink5 = Charles Lapp
| last6   = Torres-Harding   | first6 = Susan             | authorlink6 = Susan Torres-Harding
| last7   = Rowe             | first7 = Kathy             | authorlink7 = Kathy Rowe
| last8   = Gurwitt         | first8 = Alan               | authorlink8 = Alan Gurwitt
| last9   = De Meirleir     | first9 = Kenny             | authorlink9 = Kenny de Meirleir
| last10 = Van Hoof         | first10= Elke LS           | authorlink10= Elke Van Hoof
| title   = A Pediatric Case Definition for Myalgic Encephalomyelitis and Chronic Fatigue Syndrome
| journal = Journal of Chronic Fatigue Syndrome | volume = 13 | issue = 2-3 | page = 1-44
| date   = 2006
| doi     = 10.1300/J092v13n02_01
| url     = https://solvecfs.org/wp-content/uploads/2013/06/pediatriccasedefinitionshort.pdf
}}</ref>
<ref name="Strayer, 2012">{{Citation
| last1  = Strayer               | first1 = DR                   | authorlink1 = David Strayer
| last2   = Carter               | first2 = WA                   | authorlink2 = William Carter
| last3   = Stouch               | first3 = BC                   | authorlink3 =  
| last4   = Stevens               | first4 = SR                   | authorlink4 = Staci Stevens
| last5   = Bateman               | first5 = L                   | authorlink5 = Lucinda Bateman
| last6   = Cimoch               | first6 = PJ                   | authorlink6 =  
| last7   = Lapp                 | first7 = CW                   | authorlink7 = Charles Lapp  
| last8   = Peterson             | first8 = DL                   | authorlink8 = Daniel Peterson
| last9   = Chronic Fatigue Syndrome AMP-516 Study Group         | authorlink9 =  
| last10 = Mitchell             | first10 = WM                 | authorlink10 = William Mitchell  
| title   = A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.
| journal = PLoS One   | volume = 7   | issue = 3   | page = e31334
| date   = 2012
| pmid   = 22431963  
| doi     = 10.1371/journal.pone.0031334
}}
</ref>
<ref name="Unger, 2017">{{Citation
| last1  = Unger       | first1 = Elizabeth R. | authorlink1 = Elizabeth Unger
| last2   = Lin         | first2 = Jin-Mann S. | authorlink2 = Jin-Mann Sally Lin
| last3   = Tian         | first3 = Hao         | authorlink3 =  
| last4   = Natelson     | first4 = Benjamin H. | authorlink4 = Benjamin Natelson  
| last5   = Lange       | first5 = Gudrun       | authorlink5 = Gudrun Lange
| last6   = Vu           | first6 = Diana       | authorlink6 =  
| last7   = Blate       | first7 = Michelle     | authorlink7 =  
| last8   = Klimas       | first8 = Nancy G.     | authorlink8 =  Nancy Klimas
| last9   = Balbin       | first9 = Elizabeth G. | authorlink9 =
| last10   = Bateman     | first10 = Lucinda     | authorlink10 = Lucinda Bateman  
| last11   = Allen       | first11 = Ali         | authorlink11 =
| last12   = Lapp       | first12 = Charles W. | authorlink12 =  Charles Lapp  
| last13   = Springs     | first13 = Wendy       | authorlink13 =
| last14   = Kogelnik   | first14 = Andreas M. | authorlink14 = Andreas Kogelnik  
| last15   = Phan       | first15 = Catrina C. | authorlink15 =
| last16   = Danver     | first16 = Joan       | authorlink16 =
| last17   = Podell     | first17 = Richard N. | authorlink17 =  Richard Podell  
| last18   = Fitzpatrick | first18 = Trisha     | authorlink18 =
| last19   = Peterson   | first19 = Daniel L.   | authorlink19 = Daniel Peterson  
| last20   = Gottschalk | first20 = C. Gunnar   | authorlink20 =  Gunnar Gottschalk
| last21   = Rajeevan   | first21 = Mangalathu S.| authorlink21 = Mangalathu Rajeevan
| last22   = MCAM Study Group          
| title   = Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study.
| journal = American Journal of Epidemiology | volume = 1-10 | issue =   | page =  
| date   = 2017
| pmid   =  
| doi     = 10.1093/aje/kwx029
}}
</ref>
<ref name="Van Hoof, 2007">{{Citation
| last1  = Van Hoof       | first1 = E               | authorlink1 = Elke Van Hoof
| last2   = De Becker     | first2 = P               | authorlink2 = Pascale De Becker
| last3   = Lapp           | first3 = C               | authorlink3 = Charles Lapp
| last4   = Cluydts       | first4 = R               | authorlink4 =  
| last5   = De Meirleir   | first5 = K               | authorlink5 = Kenny de Meirleir
| title   = Defining the Occurrence and Influence of Alpha-Delta Sleep in Chronic Fatigue Syndrome
| journal = The American Journal of the Medical Sciences | volume = 333 | issue = 2   | page = 78-84
| date   = 2007
| pmid   = 17301585
| doi     =  
}}
</ref>
<ref name="Vojdani, 1998">{{Citation
| last1  = Vojdani     | first1 = A                   | authorlink1 =  
| last2   = Choppa       | first2 = PC                 | authorlink2 =  
| last3   = Lapp         | first3 = CW                 | authorlink3 = Charles Lapp
| title   = Downregulation of RNase L inhibitor correlates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic fatigue immune dysfunction syndrome
| journal = J Clin Lab Immunol   | volume = 50   | issue = 1   | page = 1-16
| date   = 1998
| pmid   = 10189612
| doi     =  
}}
</ref>
</references>
</references>



Latest revision as of 19:57, July 29, 2023

Source: Hunter-Hopkins Center

Charles W. Lapp, MD, is a retired Internal Medicine physician and the Medical Director Emeritus at Hunter-Hopkins Center in Charlotte, North Carolina, US, which has a practice specializing in ME/CFS, fibromyalgia, and related conditions.[1] Earlier in his career, he practiced family medicine and pediatrics in Raleigh, NC.[2] He became interested in ME/CFS following an outbreak of three small epidemics of a chronic fatiguing illness in the Raleigh area. One of these outbreaks was among all the members of the N.C. Symphony Orchestra.[3]

From 1992 to 1995 Dr. Lapp acted as Medical Director of the Cheney Clinic in Charlotte, in collaboration with Dr. Paul Cheney. In August 1995, Dr. Lapp opened the Hunter-Hopkins Center in Charlotte, North Carolina where he practiced until his retirement in 2018.[2] His center does testing for disability insurance such as the two-day cardiopulmonary exercise test (2-day CPET) and a computer-assisted cognitive function test.

Following Dr. Lapp's retirement in 2018, the Hunter-Hopkins Center director became Dr. Vincent F. Hillman with Dr. Laura Black continuing on staff.[2]

Dr. Lapp serves on the editorial board of the journal, Fatigue: Biomedicine, Health & Behavior, published on behalf of the IACFS/ME.[4]

Awards[edit | edit source]

IOM Committee on Diagnostic Criteria for ME/CFS[edit | edit source]

Dr Lapp was a reviewer for the 2015 report produced by the Institute of Medicine's Committee on Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.[6]

Pediatric Case Definition[edit | edit source]

Clinical Trials[edit | edit source]

The Hunter-Hopkins Center was one of two clinical sites participating in the Hemispherx Biopharma 511/open label Ampligen trials to gain FDA approval, which was ultimately unsuccessful. The Ampligen phase III trial results were published in 2012.[8][9] Ampligen, a brand name for Rintatolimod, is an IV medication, and was given twice weekly at the Hunter-Hopkins infusion room during the trial. The Hunter-Hopkins Center is currently one of four clinics that can administer Ampligen in the US.[9]

Clinic location[edit | edit source]

Dr Lapp retired in 2018, other physicians with expertise in ME/CFS can be contacted at the clinic he founded.

Hunter-Hopkins Center
7421 Carmel Executive Park Dr.
Charlotte, North Carolina 28226
Telephone: (704) 543-9692
Email: drlapp@drlapp.net

Notable studies[edit | edit source]

Talks and interviews[edit | edit source]

Grand Rounds Video
Grand Rounds Presentation Slide Deck

HHS/CFSAC Testimony[edit | edit source]

Open Letter to The Lancet[edit | edit source]

Three open letters to the editor of The Lancet urged the editor to commission a fully independent review of the PACE trial, which the journal had published in 2011. In 2016, Dr. Lapp, along with 42 colleagues in the ME/CFS field, signed the second letter.[22] In 2018, Dr. Lapp, with more than 100 colleagues in the ME/CFS field, signed the third letter.[23]

Online presence[edit | edit source]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  1. "Curriculum Vitae – Charles W. Lapp, MD". Hunter-Hopkins Center. Retrieved October 26, 2020.
  2. 2.0 2.1 2.2 Lapp, Charles (February 12, 2018). "Dr. Lapp Retires and Dr. Vincent Hillman Takes the Helm". Hunter-Hopkins Center. Retrieved December 23, 2018.
  3. Garloch, Karen (2009). "Cause of illness remains unknown". NewsOK.
  4. "Fatigue: Biomedicine, Health & Behavior". tandfonline.com. Retrieved November 1, 2019.
  5. "IACFS/ME Awardees". IACFS/ME. Retrieved April 23, 2020.
  6. Institute of Medicine. "ME/CFS Presentation" (PDF). National Academies Press. Retrieved December 23, 2018.
  7. Jason, Leonard A; Jordan, Karen; Miike, Teruhisa; Bell, David S; Lapp, Charles; Torres-Harding, Susan; Rowe, Kathy; Gurwitt, Alan; De Meirleir, Kenny; Van Hoof, Elke LS (2006), "A Pediatric Case Definition for Myalgic Encephalomyelitis and Chronic Fatigue Syndrome" (PDF), Journal of Chronic Fatigue Syndrome, 13 (2–3): 1–44, doi:10.1300/J092v13n02_01
  8. 8.0 8.1 Strayer, DR; Carter, WA; Stouch, BC; Stevens, SR; Bateman, L; Cimoch, PJ; Lapp, CW; Peterson, DL; Chronic Fatigue Syndrome AMP-516 Study Group; Mitchell, WM (2012), "A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.", PLoS One, 7 (3): e31334, doi:10.1371/journal.pone.0031334, PMID 22431963
  9. 9.0 9.1 Hunter-Hopkins Center. "Ampligen | Research | Hunter-Hopkins Center, P.A." Retrieved December 23, 2018.
  10. Charles W. Lapp. (1997). Management of Chronic Fatigue Syndrome in Children: A Practicing Clinician's Approach. Journal of Chronic Fatigue Syndrome, Vol. 3, Iss. 2, pp 59-76. http://dx.doi.org/10.1300/J092v03n02_07
  11. Vojdani, A; Choppa, PC; Lapp, CW (1998), "Downregulation of RNase L inhibitor correlates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic fatigue immune dysfunction syndrome", J Clin Lab Immunol, 50 (1): 1-16, PMID 10189612
  12. Aristo Vojdani & Charles W. Lapp. (1999). The Relationship Between Chronic Fatigue Syndrome and Chemical Exposure. Journal of Chronic Fatigue Syndrome, Vol. 5, Iss. 3-4, pp. 207-221. http://dx.doi.org/10.1300/J092v05n03_18
  13. Charles W. Lapp. (2006). Recognizing Pediatric CFS in the Primary Care Practice: A Practicing Clinician's Approach. Journal of Chronic Fatigue Syndrome, Vol. 13, Iss. 2-3, pp. 89-96. http://dx.doi.org/10.1300/J092v13n02_06
  14. Van Hoof, E; De Becker, P; Lapp, C; Cluydts, R; De Meirleir, K (2007), "Defining the Occurrence and Influence of Alpha-Delta Sleep in Chronic Fatigue Syndrome", The American Journal of the Medical Sciences, 333 (2): 78-84, PMID 17301585
  15. Jason, Leonard; Porter, Nicole; Shelleby, E; Till, L; Bell, David S; Lapp, Charles W; Rowe, Kathy; De Meirleir, Kenny (2009), "Severe versus Moderate criteria for the new pediatric case definition for ME/CFS", Child Psychiatry and Human Development, 40 (4): 609-20, doi:10.1007/s10578-009-0147-8
  16. Irlbeck, David M.; Vernon, Suzanne D.; McCleary, K. Kimberly; Bateman, Lucinda; Klimas, Nancy G.; Lapp, Charles W.; Peterson, Daniel L.; Brown, James R.; Remlinger, Katja S.; Wilfret, David A.; Gerondelis, Peter (2014). "No association found between the detection of either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus and chronic fatigue syndrome in a blinded, multi-site, prospective study by the establishment and use of the SolveCFS BioBank". BMC Research Notes. 7: 461. doi:10.1186/1756-0500-7-461.
  17. Unger, ER; Lin, JS; Brimmer, DJ; Lapp, CW; Komaroff, AL; Nath, A; Laird, S; Iskander, J (2016). "CDC Grand Rounds: Chronic Fatigue Syndrome — Advancing Research and Clinical Education". Morbidity and Mortality Weekly Report. 65 (5051): 1434–1438. doi:10.15585/mmwr.mm655051a4. -
  18. Unger, Elizabeth R.; Lin, Jin-Mann S.; Tian, Hao; Natelson, Benjamin H.; Lange, Gudrun; Vu, Diana; Blate, Michelle; Klimas, Nancy G.; Balbin, Elizabeth G.; Bateman, Lucinda; Allen, Ali; Lapp, Charles W.; Springs, Wendy; Kogelnik, Andreas M.; Phan, Catrina C.; Danver, Joan; Podell, Richard N.; Fitzpatrick, Trisha; Peterson, Daniel L.; Gottschalk, C. Gunnar; Rajeevan, Mangalathu S.; MCAM Study Group (2017), "Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study.", American Journal of Epidemiology, 1–10, doi:10.1093/aje/kwx029
  19. Lapp, Charles W. (January 2019). "Initiating Care Of A Patient With Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS)". Frontiers in Pediatrics. doi:10.3389/fped.2018.00415.
  20. Proskauer, Charmian; Rowe, Peter C.; Lapp, Charles W.; DeMaria, Alfred Jr; Bateman, Lucinda; Attewell, John R.; Proskauer, Daniel; Kiernicki, David J.; Adebayo, Seyi (2019). "Estimating Prevalence, Demographics, and Costs of ME/CFS Using Large Scale Medical Claims Data and Machine Learning". Frontiers in Pediatrics. 6. doi:10.3389/fped.2018.00412. ISSN 2296-2360. PMID 30671425.
  21. Campbell, Bruce. "Dr Lapp's Recommendations on Supplements | ME/CFS & Fibromyalgia Self-Help". cfidsselfhelp.org. Retrieved December 23, 2018.
  22. "Open Letter Lancet Again".
  23. "An Open Letter to The Lancet, Two Years On".
  24. Johnson, Cort (March 28, 2018). "An ME/CFS and FM Pioneer Says Good-bye: The Charles Lapp Interview". Health Rising. Retrieved December 23, 2018.